{"id":"4f-pcc","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dizziness"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It acts on the CB1 receptor, which is involved in various physiological processes, including pain modulation and mood regulation.","oneSentence":"4F-PCC is a synthetic cannabinoid receptor agonist.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:19:50.309Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of pain"}]},"trialDetails":[{"nctId":"NCT06096051","phase":"","title":"Evaluation of 4-Factor PCC in DOAC-associated Intracranial Hemorrhage","status":"COMPLETED","sponsor":"Methodist Health System","startDate":"2023-06-13","conditions":"Intracranial Hemorrhage","enrollment":76},{"nctId":"NCT07094087","phase":"PHASE3","title":"Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)","status":"RECRUITING","sponsor":"CSL Behring","startDate":"2025-09-15","conditions":"Complex Cardiovascular Surgery With Cardiopulmonary Bypass","enrollment":200},{"nctId":"NCT05156983","phase":"PHASE3","title":"A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery","status":"RECRUITING","sponsor":"Takeda","startDate":"2022-08-24","conditions":"Coagulation Disorder","enrollment":328},{"nctId":"NCT04867837","phase":"PHASE3","title":"Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor","status":"RECRUITING","sponsor":"Octapharma","startDate":"2021-09-01","conditions":"Acute Major Bleeding","enrollment":260},{"nctId":"NCT04543383","phase":"PHASE1","title":"A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-07-27","conditions":"Healthy","enrollment":52},{"nctId":"NCT05548777","phase":"","title":"Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-09-15","conditions":"Anticoagulant-related Major Bleed","enrollment":5480},{"nctId":"NCT02740335","phase":"PHASE3","title":"Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.","status":"COMPLETED","sponsor":"Octapharma","startDate":"2017-06-08","conditions":"Significant Bleeding Risk","enrollment":208},{"nctId":"NCT05738642","phase":"NA","title":"Evaluation of the Efficacy of Early Bunching of a FF-PCC in Patients With Severe Traumatic Hemorrhage","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-03-01","conditions":"Trauma","enrollment":380},{"nctId":"NCT03784794","phase":"NA","title":"Patient Blood Management for Massive Obstetric Hemorrhage","status":"COMPLETED","sponsor":"Angel Augusto Perez Calatayud","startDate":"2018-11-01","conditions":"Post Partum Hemorrhage, Fibrinogenolysis; Hemorrhage, Fibrinogen; Deficiency, Acquired","enrollment":100},{"nctId":"NCT03473132","phase":"PHASE4","title":"Assessment of Coagulation Factor Levels in Left Ventricular Device (LVAD )Patients Following Temporary Warfarin Reversal With Four Factor Prothrombin Complex Concentrate (4F-PCC)","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2018-03-15","conditions":"Anticoagulation, Anticoagulation Reversal","enrollment":50}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ACUTE KIDNEY INJURY"},{"count":1,"reaction":"CEREBRAL HAEMORRHAGE"},{"count":1,"reaction":"CEREBRAL SALT-WASTING SYNDROME"},{"count":1,"reaction":"DEEP VEIN THROMBOSIS"},{"count":1,"reaction":"DRUG INEFFECTIVE"},{"count":1,"reaction":"JUGULAR VEIN THROMBOSIS"},{"count":1,"reaction":"RENAL ARTERY THROMBOSIS"},{"count":1,"reaction":"RESPIRATORY FAILURE"},{"count":1,"reaction":"SPONTANEOUS CEREBROSPINAL FLUID LEAK SYNDROME"},{"count":1,"reaction":"URINARY TRACT INFECTION"}],"_approvalHistory":[],"publicationCount":211,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"4F-PCC","genericName":"4F-PCC","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"4F-PCC is a synthetic cannabinoid receptor agonist. Used for Treatment of pain.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}